Osimertinib with or without Chemotherapy in <i>EGFR</i>-Mutated Advanced NSCLC.

Planchard D, Jänne PA, Cheng Y, Yang JC, Yanagitani N, Kim SW, Sugawara S, Yu Y, Fan Y, Geater SL, Laktionov K, Lee CK, Valdiviezo N, Ahmed S, Maurel JM, Andrasina I, Goldman J, Ghiorghiu D, Rukazenkov Y, Todd A, Kobayashi K, FLAURA2 Investigators.

Open source

DOI: 10.1056/nejmoa2306434
Published: 2023-11-08
Container: N Engl J Med
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1056/nejmoa2306434,
  title = {Osimertinib with or without Chemotherapy in <i>EGFR</i>-Mutated Advanced NSCLC.},
  author = {Planchard D and  Jänne PA and  Cheng Y and  Yang JC and  Yanagitani N and  Kim SW and  Sugawara S and  Yu Y and  Fan Y and  Geater SL and  Laktionov K and  Lee CK and  Valdiviezo N and  Ahmed S and  Maurel JM and  Andrasina I and  Goldman J and  Ghiorghiu D and  Rukazenkov Y and  Todd A and  Kobayashi K and  FLAURA2 Investigators.},
  year = {2023},
  journal = {N Engl J Med},
  doi = {10.1056/nejmoa2306434},
  url = {https://doi.org/10.1056/nejmoa2306434}
}

RIS

TY  - JOUR
TI  - Osimertinib with or without Chemotherapy in <i>EGFR</i>-Mutated Advanced NSCLC.
AU  - Planchard D
AU  -  Jänne PA
AU  -  Cheng Y
AU  -  Yang JC
AU  -  Yanagitani N
AU  -  Kim SW
AU  -  Sugawara S
AU  -  Yu Y
AU  -  Fan Y
AU  -  Geater SL
AU  -  Laktionov K
AU  -  Lee CK
AU  -  Valdiviezo N
AU  -  Ahmed S
AU  -  Maurel JM
AU  -  Andrasina I
AU  -  Goldman J
AU  -  Ghiorghiu D
AU  -  Rukazenkov Y
AU  -  Todd A
AU  -  Kobayashi K
AU  -  FLAURA2 Investigators.
PY  - 2023
JO  - N Engl J Med
DO  - 10.1056/nejmoa2306434
UR  - https://doi.org/10.1056/nejmoa2306434
ER  -

APA

D, P., PA, J., Y, C., JC, Y., N, Y., SW, K., S, S., Y, Y., Y, F., SL, G., K, L., CK, L., N, V., S, A., JM, M., I, A., J, G., D, G., Y, R., A, T., K, K., & Investigators., F. (2023). Osimertinib with or without Chemotherapy in <i>EGFR</i>-Mutated Advanced NSCLC.. N Engl J Med. https://doi.org/10.1056/nejmoa2306434

Source records

europe-pmc · retrieved 2026-09-27T11:21:58.333Z